8-K: CEL-SCI's Multikine Seeks Saudi Breakthrough Status

CEL-SCI Corporation has filed for Breakthrough Medicine Designation for its drug Multikine with the Saudi Food and Drug Authority, partnering with Dallah Pharma for commercialization.

Summary

• A Breakthrough Medicine Designation application was filed with the Saudi Food and Drug Authority (SFDA) for Multikine (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia.
• The application was submitted by Dallah Pharma, a subsidiary of Dallah Healthcare Company (Saudi Stock Exchange Tadawul, Symbol: 4004).
• A Memorandum of Understanding (MOU) has been signed with Dallah Pharma for the commercialization of Multikine in Saudi Arabia.
• A final partnership agreement with Dallah Pharma is anticipated during the 3rd quarter of 2025.
• The SFDA's response time to a Breakthrough Medicine Designation application is approximately 60 days.
• If Breakthrough Medicine Designation is granted, Multikine would immediately become available for patient access, reimbursement, and sale in Saudi Arabia.
• Dallah Healthcare Company serves over three million patients annually through an extensive network of hospitals and specialized clinics.

Sentiment

Score: 7

Explanation: The filing indicates positive progress towards potential market entry for Multikine in Saudi Arabia through a strategic partnership and an accelerated regulatory pathway, suggesting a favorable outlook, though approval is not guaranteed.

Positives

• The filing for Breakthrough Medicine Designation could significantly accelerate market entry and patient access for Multikine in Saudi Arabia.
• The partnership with Dallah Pharma, a premier pharmaceutical and healthcare company serving over three million patients annually, provides a strong commercialization channel.
• Expected immediate availability for patient access and reimbursement/sale upon designation approval could lead to rapid market penetration.
• The anticipation of a final partnership agreement in Q3 2025 indicates concrete progress towards commercialization.

Negatives

• There is no guarantee that the Breakthrough Medicine Designation application will be approved by the SFDA.
• The final partnership agreement with Dallah Pharma is still pending and expected in Q3 2025, meaning it is not yet a finalized deal.
• The filing does not disclose any specific financial terms or revenue projections related to the potential commercialization.

Risks

• The Saudi Food and Drug Authority (SFDA) may not grant Breakthrough Medicine Designation for Multikine.
• The final partnership agreement with Dallah Pharma may not be successfully concluded during the 3rd quarter of 2025 or at all.
• Even with designation, regulatory hurdles or market acceptance challenges in Saudi Arabia could impact Multikine's commercial success.

Future Outlook

The company anticipates that a final partnership agreement with Dallah Pharma for the commercialization of Multikine in Saudi Arabia will be concluded during the 3rd quarter of 2025. Following a potential Breakthrough Medicine Designation approval from the SFDA, which is expected within approximately 60 days, Multikine would become immediately available for patient access and reimbursement/sale in Saudi Arabia.

Management Comments

• Management reported the filing of a Breakthrough Medicine Designation application with the Saudi Food and Drug Authority (SFDA) for Multikine (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia by one of the Kingdom's premier pharmaceutical and healthcare companies.

Industry Context

This development aligns with a global trend of pharmaceutical companies seeking accelerated regulatory pathways for innovative treatments in emerging markets, particularly in the Middle East, where healthcare infrastructure and investment are rapidly expanding. Partnerships with established local players like Dallah Pharma are crucial for navigating regional regulatory landscapes and distribution networks.

Stakeholder Impact

• Shareholders: Potential for increased market access and revenue streams for Multikine, subject to regulatory approval and partnership finalization.
• Patients in Saudi Arabia: Potential for earlier access to Multikine if Breakthrough Medicine Designation is granted.
• Dallah Pharma/Healthcare: Expansion of their product portfolio and healthcare services.

Next Steps

• SFDA to review the Breakthrough Medicine Designation application (expected response within approximately 60 days).
• Finalization of the partnership agreement with Dallah Pharma (expected during Q3 2025).
• Upon designation approval, Multikine will become available for patient access, reimbursement, and sale in Saudi Arabia.

Key Dates

Recommendation

The filing presents a positive development with the potential for Multikine to enter the Saudi Arabian market via an accelerated regulatory pathway and a strong local partner. However, the Breakthrough Medicine Designation is not yet granted, and the final partnership agreement is still pending. While the news is favorable, the contingent nature of these events warrants a 'hold' recommendation until further definitive approvals and financial terms are disclosed, allowing investors to assess the certainty and magnitude of future revenue streams.

Keywords

CEL-SCI, Multikine, Breakthrough Medicine Designation, Saudi Arabia, SFDA, Dallah Pharma, Biotechnology, Pharmaceuticals, Commercialization, Regulatory Approval